{"id":2457012,"date":"2026-11-03T02:53:31","date_gmt":"2026-11-03T01:53:31","guid":{"rendered":"https:\/\/kohenavocats.com\/olmesartan-what-patients-should-check-after-a-medication-recall\/"},"modified":"2026-11-03T02:53:31","modified_gmt":"2026-11-03T01:53:31","slug":"olmesartan-what-patients-should-check-after-a-medication-recall","status":"publish","type":"post","link":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/","title":{"rendered":"Olmesartan: What Patients Should Check After a Medication Recall"},"content":{"rendered":"<p>Seeing a medication name in a recall headline can raise two separate questions: is the medicine in your possession actually covered, and what should you preserve if you experienced a medical problem or expense? Start by checking the complete product name, strength and lot with your pharmacist or prescribing clinician. Do not change or stop a prescribed blood-pressure medicine on your own because of a headline. If you have urgent symptoms, seek urgent medical care.<\/p>\n<p>The <a href=\"https:\/\/www.pharmacy.ca.gov\/about\/recall_alerts\/102326_macleods.pdf\">California Board of Pharmacy recall notice<\/a> describes a voluntary retail-and-pharmacy-level recall of a particular three-ingredient tablet containing olmesartan medoxomil, amlodipine and hydrochlorothiazide. It identifies two lots and reports a dissolution test outside the specification. The manufacturer&#8217;s assessment, reproduced in the notice, reported no adverse-event or spontaneous safety reports for the tested lot, considered the probability of serious adverse health consequences remote, and did not expect a consumer safety risk under the labeled conditions. These are specific facts about that notice; they do not establish what happened to any individual patient.<\/p>\n<p>For a potential claim, the practical work is to separate product identification, a health event, medical causation and any financial loss. Federal law and the applicable state&#8217;s law can affect different parts of that analysis. The discussion of the decisions below is general in scope: it describes checks useful in comparable situations and makes no findings about the parties named in those cases.<\/p>\n<h2>I. Does the recall apply to your medicine, and what should you preserve?<\/h2>\n<h3>A. Match the actual product before drawing conclusions<\/h3>\n<p>The notice identifies olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets at a combined strength of 40 mg, 10 mg and 12.5 mg. It lists lot 12251163A for the 30-count package and lot 12251163B for the 90-count package, with an expiration of May 2027. The notice states that the affected batch was distributed between November 21, 2025 and April 27, 2026. A search result for olmesartan alone is not enough to show that a different strength, a single-ingredient tablet, a different combination or another lot is included.<\/p>\n<p>The difference between a prescription label and a manufacturer&#8217;s package matters. A pharmacy label often identifies the patient, drug and dispensing date but may not show the original lot. If that is your situation, ask the pharmacy whether its dispensing records or packaging can identify the lot, and record what it actually confirms. A receipt or bottle establishes useful parts of the history, but it should not be described as proof of the lot if the number is missing. Keep an unanswered question as an unanswered question instead of filling it in from a news report.<\/p>\n<p>The notice describes a test on the 90-count lot in which the mean dissolution result for the olmesartan component was 79% against a stated requirement of at least 80%. It says each individual unit met the unit-level criteria, while the mean did not meet the stated stage-three acceptance criteria. The same notice says the assay, related substances and dissolution of the other two ingredients complied with specifications. A patient cannot determine how one tablet performed in the body merely from the batch test. The notice describes a possible reduction or delay in absorption and a potential temporary, medically reversible reduction in blood-pressure control; it does not establish that this occurred to a particular person.<\/p>\n<p>Federal recall terminology also has a distribution meaning. Under <a href=\"https:\/\/ecfr.gov\/current\/title-21\/chapter-I\/subchapter-A\/part-7\/subpart-C\/section-7.42\">21 C.F.R. \u00a7 7.42<\/a>, a recall strategy identifies its depth in the distribution chain, which may be consumer, retail or wholesale level. The board&#8217;s notice describes this action at the retail and pharmacy level. That description is a reason to ask the dispensing pharmacy how its notice applies to your supply; it is not a statement that every bottle containing the same active ingredient has been recalled or that a court has ordered compensation.<\/p>\n<p>The FDA&#8217;s <a href=\"https:\/\/fda.gov\/safety\/industry-guidance-recalls\/recalls-background-and-definitions\">recall definitions<\/a> explain that recalls may begin on a firm&#8217;s initiative, at the agency&#8217;s request or by an FDA order under statutory authority. The FDA describes several recall classes according to health consequences. Do not assign a class to an individual bottle from those general definitions alone: use the actual notice or an identified agency record for the specific recall. Even where a classification is known, it describes a regulatory assessment, not a diagnosis of a particular patient.<\/p>\n<p>Federal <a href=\"https:\/\/ecfr.gov\/current\/title-21\/section-7.40\">21 C.F.R. \u00a7 7.40<\/a> describes recall as a method for removing or correcting products and recognizes its voluntary character in the framework addressed by the regulation. A recall and a lawsuit have different purposes. A recall may help remove affected stock; a civil claim asks a court to resolve a particular claim under the governing law. The presence of the first does not automatically establish every element of the second.<\/p>\n<p>Preserve the physical and digital identifiers without interrupting care. Photograph the bottle, label, lot and expiration where visible; keep any written recall message and the accompanying instructions. If a pharmacy needs the package returned or disposed of, ask how to document it first and follow its directions. A photograph is useful, but note whether the lot comes from the original package or a later pharmacy confirmation. Do not take extra doses, keep taking a product contrary to a clinician&#8217;s instructions, or attempt an unsupervised experiment to see whether a medicine works.<\/p>\n<p>A practical record can also include the prescription order, refill history, the pharmacy&#8217;s name, dispensing dates and any change in the appearance or packaging of a refill. Where a household uses multiple pharmacies or receives mail-order refills, distinguish the supply from each one. Keep original files if possible and make working copies. If the container was discarded, write that down and ask what alternative records are available; an honest gap in the record is more useful than a guessed batch number.<\/p>\n<h3>B. Separate medical observations from proof of a drug-related injury<\/h3>\n<p>Write down the sequence in ordinary language: when the medication was dispensed, when it was taken as prescribed, when a change in symptoms or measurements was noticed, and when a clinician was consulted. Include the dates of relevant appointments and tests, and keep the results in the form the provider supplied them. If a measurement came from a home device, record the reading and circumstances without changing it to make the sequence look more convincing. A timeline helps a clinician assess what occurred; it does not establish the cause.<\/p>\n<p>Blood-pressure changes can have several possible explanations, including changes in health, other medicines or how and when measurements were taken. A clinician can assess the significance of a particular reading in the patient&#8217;s medical context. The recall notice&#8217;s description of a potential effect is not a substitute for that assessment. Equally, the absence of a report in the manufacturer&#8217;s assessment for the tested lot is a description of the information it had, not a determination about every person&#8217;s experience.<\/p>\n<p>The FDA&#8217;s <a href=\"https:\/\/fda.gov\/safety\/medwatch-fda-safety-information-and-adverse-event-reporting-program\/information-about-reporting-adverse-events-fdas-medwatch-program\">MedWatch reporting guidance<\/a> says health professionals and consumers can report serious problems they believe may be associated with a medical product, including suspected quality problems and therapeutic failures. The agency also explains that a report alone rarely confirms causation. A report can therefore be a useful safety signal and a record of what was observed, while a separate medical and legal analysis may be needed to assess an individual&#8217;s claim.<\/p>\n<p>When preparing a report or a question for a clinician, distinguish observation from interpretation. For example, a patient can identify a measurement, an appointment, a hospital visit, the drug and dose used, and whether the lot has been verified. If the patient does not know what caused a symptom, say so. Include other relevant medicines and a preexisting condition where appropriate, because these may change how a health professional evaluates the episode. Do not omit facts that complicate the proposed explanation.<\/p>\n<p>Federal <a href=\"https:\/\/ecfr.gov\/current\/title-21\/section-314.80\">21 C.F.R. \u00a7 314.80<\/a> separately addresses postmarketing adverse-drug-experience review and reporting by applicants and certain other covered persons. It defines an adverse drug experience broadly, including an event associated with drug use whether or not considered drug related. That regulatory definition should not be confused with a finding that a manufacturer caused an injury. The reporting duties in the regulation and an individual&#8217;s decision to report through MedWatch are distinct processes.<\/p>\n<p>Keep the records of the consequences as well as the event itself. An explanation-of-benefits statement, a bill, a pharmacy receipt, a transportation receipt or an employer&#8217;s record may help establish what was paid, what was covered and what remains disputed. Separate a charge from the amount actually paid and from reimbursement. If a clinician changed treatment, note what the clinician recommended and when; do not describe the change as proof of a defective product unless that conclusion is supported by the medical evidence.<\/p>\n<p>Privacy matters when sharing a medical history. Give relevant records to the health professionals and other recipients who need them, and check which information a form requests before sending it. A concise chronology can refer to supporting records without placing an entire medical file in a public social-media post. Preserve a copy of the version submitted and any response, but do not assume that an agency report starts a private lawsuit or determines its outcome.<\/p>\n<h2>II. When could a patient have a claim, and what do comparable decisions show?<\/h2>\n<h3>A. Identify the product, the proposed legal theory and the jurisdiction<\/h3>\n<p>A potential claim is not just a concern about a medicine. The first questions are which product the patient received, what harm or expense is claimed, what conduct or product condition is alleged, and which entity had the relevant role. A manufacturing issue, an allegedly inadequate warning and a prescribing or dispensing issue are different questions. Their requirements can differ under the applicable state&#8217;s law, and federal law may limit a particular theory. Keep those distinctions visible before drawing a conclusion about whether any claim is available.<\/p>\n<p>In <a href=\"https:\/\/courtlistener.com\/opinion\/219510\/pliva-inc-v-mensing\/\">PLIVA, Inc. v. Mensing<\/a>, 564 U.S. 604 (2011), decided June 23, 2011 by the Supreme Court of the United States, the Court held that federal law preempted the particular Minnesota and Louisiana failure-to-warn claims against generic-drug manufacturers because the manufacturers could not independently make the label change demanded by those claims. For a patient evaluating a generic medicine, the useful first check is exactly which warning, product and legal duty are alleged; the decision does not itself resolve every possible theory concerning a recalled lot. In <a href=\"https:\/\/supremecourt.gov\/opinions\/25pdf\/24-889_5i36.pdf\">Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.<\/a>, No. 24-889 (U.S. Jun. 4, 2026), decided June 4, 2026 by the Supreme Court of the United States, the Court cited Mensing&#8217;s generic-label sameness principle in a patent-inducement dispute; that citation was not a decision on a patient&#8217;s recall injury.<\/p>\n<p>The comparison makes the label relevant without making it the only document worth keeping. A generic product&#8217;s identity and approved labeling can affect the analysis of a warning theory. A claim concerning a particular batch, however, must be evaluated on its own facts and legal basis; the fact that the subject is a generic drug does not by itself answer every question about a product&#8217;s manufacture, distribution or dispensing. No conclusion about a specific possible defendant follows simply from a receipt or recall notice.<\/p>\n<p>In <a href=\"https:\/\/govinfo.gov\/content\/pkg\/USCOURTS-ohnd-1_24-md-03092\/pdf\/USCOURTS-ohnd-1_24-md-03092-2.pdf\">Bennett v. Indivior Inc.<\/a>, No. 1:24-sf-65011 (N.D. Ohio Dec. 31, 2024), decided December 31, 2024 by the United States District Court, Northern District of Ohio, the court granted a motion to dismiss in part and denied it in part, allowing the specified pre-approval design-defect claims and a failure-to-warn claim against the new-drug application holder to proceed. The court was applying Ohio law and federal preemption principles to allegations about a different, brand-name product at the pleading stage. For a reader comparing possible theories, the decision illustrates why the product&#8217;s regulatory status, the specific theory and the procedural stage must be identified separately; it did not decide liability for this recall.<\/p>\n<p>Bennett is a federal district court decision applying Ohio law; it is not a nationwide ruling that every warning or design claim survives. Mensing is a Supreme Court decision about a particular conflict between federal generic-label requirements and the state duties asserted in that litigation. They can be read together without forcing the same result onto different facts. A claim involving a California resident, for example, needs an analysis of California law and the actual product, as well as any relevant federal constraints. A medical event in another state may require a different state-law analysis.<\/p>\n<p>Product identification can become more complex when a pharmacy dispenses a medicine in a new container or a patient changes pharmacies. Ask for records that identify the product actually supplied on each relevant date. The name on a prescription, the product on an insurance statement, and the manufacturer and lot of the dispensed item answer different questions. If any of them differs from the recall notice, preserve that difference; it may determine whether the recall has any direct connection to the patient&#8217;s supply.<\/p>\n<p>Consider the claimed loss with the same care. A request for a replacement, a disputed pharmacy charge and a claim for an injury have different factual foundations. A patient who received a replacement but had no medical problem should not be described as having suffered an injury merely because the lot was recalled. Someone who experienced a health problem should retain the relevant clinical records and expenses without assuming that each was caused by the medicine. The answer depends on the evidence and the applicable legal theory.<\/p>\n<p>Keep notices and responses in their original context. A pharmacy&#8217;s confirmation of the product it dispensed may be evidence of identity; a laboratory result may be evidence of a measured condition; a recall notice may describe the product and the action taken. None automatically proves the others. If a document contains a correction or a later response, retain both versions and note the date received. This lets a reviewer distinguish what was known at the time from what was learned afterward.<\/p>\n<h3>B. Build a reliable causation and loss record<\/h3>\n<p>In <a href=\"https:\/\/courtlistener.com\/opinion\/4396853\/stephen-wendell-v-glaxosmithkline-llc\/\">Wendell v. GlaxoSmithKline LLC<\/a>, 858 F.3d 1227 (9th Cir. 2017), decided June 2, 2017 by the United States Court of Appeals, Ninth Circuit, the court reversed summary judgment after finding that the trial court had assessed the proposed medical experts&#8217; methods too narrowly on the record before it. For a patient considering a possible medicine-related claim, the practical lesson is to preserve the complete medical history and evidence of other possible causes so a qualified expert can assess a reliable method. The court did not award damages or decide that the present recalled medicine caused an injury. In <a href=\"https:\/\/cdn.ca9.uscourts.gov\/datastore\/opinions\/2024\/03\/05\/22-16465.pdf\">Jones v. Riot Hospitality Group LLC<\/a>, No. 22-16465 (9th Cir. Mar. 5, 2024), decided March 5, 2024 by the United States Court of Appeals for the Ninth Circuit, the court cited Wendell for a flexible inquiry into expert evidence in an unrelated electronic-discovery dispute; it was not a ruling about this recall.<\/p>\n<p>In federal court, <a href=\"https:\/\/govinfo.gov\/content\/pkg\/USCODE-2024-title28\/html\/USCODE-2024-title28-app-federalru-dup2-rule702.htm\">Federal Rule of Evidence 702<\/a> addresses testimony by a qualified expert. It requires the proponent to demonstrate to the court, more likely than not, that the testimony will help the fact finder, rests on sufficient facts or data, uses reliable principles and methods, and reflects a reliable application to the facts. The current rule, amended in 2023, matters when evaluating an older opinion: the case&#8217;s result on its own record is not a promise that a different expert&#8217;s opinion will be admitted.<\/p>\n<p>That distinction helps explain why a reliable chronology matters. A medical professional may need to know which formulation was used, how consistently it was taken, the patient&#8217;s baseline condition, the timing of a change, and any other plausible explanation. A legal reviewer may also need to distinguish whether a warning was available to the prescriber and whether a different warning would have mattered on the particular facts. Those questions cannot be answered from a recall headline. A patient can help by preserving accurate documents rather than attempting to supply a scientific conclusion.<\/p>\n<p>If a medical record contains an error, ask the provider about its correction process instead of silently changing your own copy. If it contains uncertainty, keep that uncertainty visible. A patient can write a separate note explaining what they remember and when the note was created. A later recollection, a contemporaneous record and a clinician&#8217;s observation have different origins; retaining those distinctions makes the material easier to evaluate. Do the same for photographs and saved messages, including the date and source when known.<\/p>\n<p>Financial records should tell a similarly precise story. Group bills by appointment or service, show insurance adjustments and reimbursement separately, and identify any cost that was later refunded. If time away from work is claimed, keep the relevant schedule and employer records along with the basis for the calculation. Do not count the same charge twice or assume that every cost following a recall is legally recoverable. Whether a category of loss can be recovered depends on the applicable law and the proof in the individual matter.<\/p>\n<p>For an adverse-event report, include the product identifier only to the extent known and distinguish a verified lot from an inferred one. If a pharmacist later confirms a different lot, preserve the correction and provide it to the relevant recipient. A record that evolves transparently is more useful than a confident but unsupported first account. Reports can help the FDA identify possible safety issues, while the agency&#8217;s own guidance cautions that a report alone rarely establishes a causal relationship.<\/p>\n<p>Finally, distinguish a court&#8217;s procedural ruling from a final outcome. A decision allowing a claim to proceed means that the court applied a legal standard to the record at that stage; it does not necessarily decide what a later fact finder will conclude. A reversal of summary judgment likewise returns an issue for further proceedings under the court&#8217;s directions rather than awarding an automatic recovery. These distinctions are central when using decisions about different medicines as examples.<\/p>\n<h2>Conclusion<\/h2>\n<p>For the identified olmesartan combination recall, first verify the complete drug, strength and lot with the pharmacy and keep treatment decisions with the prescribing clinician. Preserve the notice, dispensing information, medical chronology and documented expenses without assuming that a recall proves personal harm. If a specific legal question arises, identify the applicable state, the exact product, the proposed theory and the evidence needed to evaluate causation and loss. Federal rules and the comparable decisions above show why each of those questions must be answered on its own facts.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>How to identify the affected olmesartan combination lots, preserve medical records and evaluate the legal questions raised by a recall.<\/p>\n","protected":false},"author":232070755,"featured_media":9620,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_kj_source_type":"","_kj_official_id":"","_kj_official_url":"","_kj_judilibre_id":"","_kj_jur":"","_kj_lieu":"","_kj_chambre":"","_kj_rg":"","_kj_date":"","footnotes":""},"categories":[523780,523774],"tags":[],"class_list":["post-2457012","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-us-civil-law","category-us-law"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Olmesartan: What Patients Should Check After a Medication Recall<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olmesartan: What Patients Should Check After a Medication Recall\" \/>\n<meta property=\"og:description\" content=\"How to identify the affected olmesartan combination lots, preserve medical records and evaluate the legal questions raised by a recall.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/\" \/>\n<meta property=\"og:site_name\" content=\"Hassan KOHEN\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-03T01:53:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kohenavocats.com\/wp-content\/uploads\/2026\/11\/kohen-avocats-partage.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kohen\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kohen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/olmesartan-what-patients-should-check-after-a-medication-recall\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/olmesartan-what-patients-should-check-after-a-medication-recall\\\/\"},\"author\":{\"name\":\"Kohen\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#\\\/schema\\\/person\\\/761c9ba54fa1ca84d405cef0831ff751\"},\"headline\":\"Olmesartan: What Patients Should Check After a Medication Recall\",\"datePublished\":\"2026-11-03T01:53:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/olmesartan-what-patients-should-check-after-a-medication-recall\\\/\"},\"wordCount\":3059,\"publisher\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/olmesartan-what-patients-should-check-after-a-medication-recall\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kohenavocats.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/chris-barbalis-r4ytn1RdQas-unsplash.webp\",\"articleSection\":[\"U.S. Civil &amp; Consumer Law\",\"U.S. Law\"],\"inLanguage\":\"en-US\",\"citation\":\"Olmesartan: What Patients Should Check After a Medication Recall\",\"about\":[{\"@type\":\"Thing\",\"name\":\"U.S. Civil & Consumer Law\"},{\"@type\":\"Thing\",\"name\":\"U.S. Law\"}],\"dateModified\":\"2026-11-03T01:53:31+00:00\",\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\".article-content > p:first-of-type\"]}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/olmesartan-what-patients-should-check-after-a-medication-recall\\\/\",\"url\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/olmesartan-what-patients-should-check-after-a-medication-recall\\\/\",\"name\":\"Olmesartan: What Patients Should Check After a Medication Recall\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/olmesartan-what-patients-should-check-after-a-medication-recall\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/olmesartan-what-patients-should-check-after-a-medication-recall\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kohenavocats.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/chris-barbalis-r4ytn1RdQas-unsplash.webp\",\"datePublished\":\"2026-11-03T01:53:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/olmesartan-what-patients-should-check-after-a-medication-recall\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kohenavocats.com\\\/en\\\/olmesartan-what-patients-should-check-after-a-medication-recall\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/olmesartan-what-patients-should-check-after-a-medication-recall\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kohenavocats.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/chris-barbalis-r4ytn1RdQas-unsplash.webp\",\"contentUrl\":\"https:\\\/\\\/kohenavocats.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/chris-barbalis-r4ytn1RdQas-unsplash.webp\",\"width\":2994,\"height\":3919},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/olmesartan-what-patients-should-check-after-a-medication-recall\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olmesartan: What Patients Should Check After a Medication Recall\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/\",\"name\":\"Hassan KOHEN\",\"description\":\"Ma\u00eetre Hassan Kohen, avocat p\u00e9naliste \u00e0 Paris, intervient exclusivement en droit p\u00e9nal pour la d\u00e9fense des particuliers, notamment en mati\u00e8re d\u2019accusations de viol. Il assure un accompagnement rigoureux d\u00e8s la garde \u00e0 vue jusqu\u2019\u00e0 la Cour d\u2019assises, veillant au strict respect des garanties proc\u00e9durales.\",\"publisher\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#organization\",\"name\":\"Hassan KOHEN\",\"url\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/kohenavocats.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Logo-2-1.webp\",\"contentUrl\":\"https:\\\/\\\/kohenavocats.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Logo-2-1.webp\",\"width\":2114,\"height\":1253,\"caption\":\"Hassan KOHEN\"},\"image\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#\\\/schema\\\/person\\\/761c9ba54fa1ca84d405cef0831ff751\",\"name\":\"Kohen\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1c5e76ef76bbbfdd2b4da984e2bf2fa4056fd51a27d25ce2c332047f1dfd6e00?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1c5e76ef76bbbfdd2b4da984e2bf2fa4056fd51a27d25ce2c332047f1dfd6e00?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1c5e76ef76bbbfdd2b4da984e2bf2fa4056fd51a27d25ce2c332047f1dfd6e00?s=96&d=identicon&r=g\",\"caption\":\"Kohen\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/hassan-kohen-448548192\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@Kohen-Avocats\"],\"url\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/author\\\/kohenmlk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Olmesartan: What Patients Should Check After a Medication Recall","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/","og_locale":"en_US","og_type":"article","og_title":"Olmesartan: What Patients Should Check After a Medication Recall","og_description":"How to identify the affected olmesartan combination lots, preserve medical records and evaluate the legal questions raised by a recall.","og_url":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/","og_site_name":"Hassan KOHEN","article_published_time":"2026-11-03T01:53:31+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2026\/11\/kohen-avocats-partage.jpg","type":"image\/jpeg"}],"author":"Kohen","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Kohen","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/#article","isPartOf":{"@id":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/"},"author":{"name":"Kohen","@id":"https:\/\/kohenavocats.com\/en\/#\/schema\/person\/761c9ba54fa1ca84d405cef0831ff751"},"headline":"Olmesartan: What Patients Should Check After a Medication Recall","datePublished":"2026-11-03T01:53:31+00:00","mainEntityOfPage":{"@id":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/"},"wordCount":3059,"publisher":{"@id":"https:\/\/kohenavocats.com\/en\/#organization"},"image":{"@id":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/#primaryimage"},"thumbnailUrl":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2024\/11\/chris-barbalis-r4ytn1RdQas-unsplash.webp","articleSection":["U.S. Civil &amp; Consumer Law","U.S. Law"],"inLanguage":"en-US","citation":"Olmesartan: What Patients Should Check After a Medication Recall","about":[{"@type":"Thing","name":"U.S. Civil & Consumer Law"},{"@type":"Thing","name":"U.S. Law"}],"dateModified":"2026-11-03T01:53:31+00:00","speakable":{"@type":"SpeakableSpecification","cssSelector":[".article-content > p:first-of-type"]}},{"@type":"WebPage","@id":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/","url":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/","name":"Olmesartan: What Patients Should Check After a Medication Recall","isPartOf":{"@id":"https:\/\/kohenavocats.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/#primaryimage"},"image":{"@id":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/#primaryimage"},"thumbnailUrl":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2024\/11\/chris-barbalis-r4ytn1RdQas-unsplash.webp","datePublished":"2026-11-03T01:53:31+00:00","breadcrumb":{"@id":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/#primaryimage","url":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2024\/11\/chris-barbalis-r4ytn1RdQas-unsplash.webp","contentUrl":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2024\/11\/chris-barbalis-r4ytn1RdQas-unsplash.webp","width":2994,"height":3919},{"@type":"BreadcrumbList","@id":"https:\/\/kohenavocats.com\/en\/olmesartan-what-patients-should-check-after-a-medication-recall\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/kohenavocats.com\/en\/"},{"@type":"ListItem","position":2,"name":"Olmesartan: What Patients Should Check After a Medication Recall"}]},{"@type":"WebSite","@id":"https:\/\/kohenavocats.com\/en\/#website","url":"https:\/\/kohenavocats.com\/en\/","name":"Hassan KOHEN","description":"Ma\u00eetre Hassan Kohen, avocat p\u00e9naliste \u00e0 Paris, intervient exclusivement en droit p\u00e9nal pour la d\u00e9fense des particuliers, notamment en mati\u00e8re d\u2019accusations de viol. Il assure un accompagnement rigoureux d\u00e8s la garde \u00e0 vue jusqu\u2019\u00e0 la Cour d\u2019assises, veillant au strict respect des garanties proc\u00e9durales.","publisher":{"@id":"https:\/\/kohenavocats.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kohenavocats.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kohenavocats.com\/en\/#organization","name":"Hassan KOHEN","url":"https:\/\/kohenavocats.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kohenavocats.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2026\/01\/Logo-2-1.webp","contentUrl":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2026\/01\/Logo-2-1.webp","width":2114,"height":1253,"caption":"Hassan KOHEN"},"image":{"@id":"https:\/\/kohenavocats.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/kohenavocats.com\/en\/#\/schema\/person\/761c9ba54fa1ca84d405cef0831ff751","name":"Kohen","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1c5e76ef76bbbfdd2b4da984e2bf2fa4056fd51a27d25ce2c332047f1dfd6e00?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1c5e76ef76bbbfdd2b4da984e2bf2fa4056fd51a27d25ce2c332047f1dfd6e00?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1c5e76ef76bbbfdd2b4da984e2bf2fa4056fd51a27d25ce2c332047f1dfd6e00?s=96&d=identicon&r=g","caption":"Kohen"},"sameAs":["https:\/\/www.linkedin.com\/in\/hassan-kohen-448548192\/","https:\/\/www.youtube.com\/@Kohen-Avocats"],"url":"https:\/\/kohenavocats.com\/en\/author\/kohenmlk\/"}]}},"_links":{"self":[{"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/posts\/2457012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/users\/232070755"}],"replies":[{"embeddable":true,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/comments?post=2457012"}],"version-history":[{"count":0,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/posts\/2457012\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/media\/9620"}],"wp:attachment":[{"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/media?parent=2457012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/categories?post=2457012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/tags?post=2457012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}